Glenmark Pharmaceuticals
Mr. Ulhas Dhuppad is the President and head of Global Pharmaceutical Development at Glenmark. He is responsible for driving generics research, specialty formulations, global regulatory affairs, and project management. He brings with him rich experience spanning more than three decades. In this duration, he has developed more than 300 products including complex generics for USA and Europe and many specialty products for emerging markets. Ulhas has been instrumental in designing development strategies and successfully filing niche products and has expertise in development of complex dosage forms. His areas of focus include setting of systems for robust and in time product development.
Mr. Dhuppad has worked in leading pharmaceutical companies like Cadila Laboratories, Cipla, Lupin, and Morepen Laboratories. He has been previously associated with Glenmark for 15 years leading CMC development, and during this period was a key contributor in building the Global Formulations R&D function. More recently, he was President – R&D at Alkem Laboratories.
Mr. Dhuppad holds a Master’s Degree in Pharmacy from Pune University.
This person is not in any offices
Glenmark Pharmaceuticals
5 followers
Glenmark Pharmaceuticals Limited is a global pharmaceutical company. The Company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW). It has approximately seven molecules, over two NCEs and approximately five NBEs in various stages of pre-clinical and clinical development. It is focused on developing and marketing branded and generic formulations. It focuses on manufacturing products across therapeutic areas of dermatology, respiratory and oncology. Its active pharmaceuticals ingredients (API) business spans over 80 countries, including regulated markets of the United States, Europe, Japan and Canada. Its products are primarily marketed in the United States and Western Europe. It has offices in over 40 countries, and operates approximately 20 manufacturing facilities in over five countries. It operates over five research and development (R&D) centers.